Introduction
Understanding differences in HTA outcomes across markets remains challenging due to variation in assessment frameworks and the volume of available decision documentation
Agorva is Remap Consulting’s AI-enabled HTA and market access intelligence platform, purpose-built to support structured analysis of HTA and reimbursement decisions. It brings together published HTA and regulatory decisions from multiple agencies in a structured, searchable and traceable dataset that continuously ingests published HTA and regulatory decisions from multiple agencies
This study used that AI-enabled market access intelligence platform to identify and compare lung cancer assessment outcomes across England and Germany, and to explore potential drivers of outcome variation
Authors: Lauren Boland, PhD; Tomas Keating MSc
Objectives
- To assess the access in England and Germany of lung cancer treatments over a 5-year period
- To use an AI-enabled market access intelligence platform to source the information required for the assessment
Conclusions
Agorva enabled:
- Rapid structured comparison of 76 lung cancer assessments across England and Germany
- Cross-market comparison, highlighting the differences in outcome between NICE and the G-BA
- Clear visibility of the factors driving each assessment decision
- Paragraph-level traceability to the original decision source